Waleed Alselwi1, Thomas Coventary2, Faisal Azam1

Slides:

Advertisements

Similar presentations

RecommendationsRecommendations Risk Recommendation Ambulation (all pts) IPC/GCS or, UFH 5000 SQ q 12 hrs or, Enoxaparin 40mg SQ daily IPC/GCS or, UFH 5000.

Advertisements

ANDREW NG PRINCE OF WALES HOSPITAL Role of primary chemoradiation in esophageal carcinoma.

UK Renal Registry 14th Annual Report Figure 8.1. Median haemoglobin for incident dialysis patients at start of dialysis treatment in 2010.

Prognostic factors for breast cancer survival in affluent and deprived areas Jasmina Stefoski-Mikeljevic.

The All Breast Cancer Report was published in October breastscreen/research.html#breast- cancer-report.

Background The 2 week wait referral system was designed to expedite the referral of patients, suspected to have cancer, from Primary to Secondary care.

Vascular issues associated with bevacizumab Stuart M. Lichtman, MD, FACP 65+ Clinical Geriatric Program Associate Attending Memorial Sloan-Kettering Cancer.

Evaluating the Performance of a Previously Reported Risk Score to Predict Venous Thromboembolism: A VERITY Registry Study Denise O'Shaughnessy, Peter Rose,

Clinical features and outcome in ovarian sarcomas: Analysis of a single-institution experience A López Pousa, X Gonzàlez Farré, MJ. Quintana, S Bagué,

Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer Agnelli G et al. N Engl J Med 2012;366(7): George D et al. Proc.

The Role of Thromboprophylaxis in Elective Spinal Surgery The Role of Thromboprophylaxis in Elective Spinal Surgery VA Elwell, N Koo Ng, D Horner & D Peterson.

Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.

Chemotherapy Audit  Audit of patients who died within three months of their last dose of chemotherapy at Airedale General Hospital  The records of 50.

Higher Incidence of Venous Thromboembolism (VTE) in the Outpatient versus Inpatient Setting Among Patients with Cancer in the United States Khorana A et.

Gray Zone Lymphoma (GZL) with Features Intermediate between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective.

Univariate Analyses Treatment Outcome And Patterns Of Relapse Following Adjuvant Carboplatin For Stage I Testicular Seminoma: Results From a 17 Year UK.

Conclusions Results Methods Background Venous thrombo-embolism in patients undergoing neoadjuvant chemotherapy and surgery for oesophago-gastric cancer.

Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patients Thrombosis Research (2008)

VTE prophylaxis Sharif-Kashani,B.MD SBMU Preventing VTE Over 12 million people in the United States are at risk of VTE due to hospitalization for major.

UK Hospitalizations due to Stroke in Prostate Cancer Patients

Chapter 9: Vascular Complications of Cancer and Cancer Treatment

Taylor Butler, PharmD, BCOP Decentralized Clinical Pharmacist

NEOADJUVANT CHEMOTHERAPY FOR ADVANCED ENDOMETRIAL CANCER

Brain imaging prior to lung cancer resection

Supplemental Figure 1: FOXM1 mRNA level analysis in 48 ovarian tissues

The VERITY Steering Committee

Venous Thromboembolism Prophylaxis (VTE)

San Antonio Breast Cancer Symposium - December 6-10, 2011 Pre-operative haematological markers and prognosis in early breast cancer Cordiner RL1, Mansell.

Figure #1 Overall survival Figure #2 Disease free survival

Fig. 3 Overall and disease-free survival of single-zone metastasis group according to the number of stations involved. No significant differences were.

Evaluating The Accuracy Of International Classification Of Diseases 10TH Revision Codes For Venous Thromboembolism (VTE) And Major Bleeding (MB) in.

UNDERSTANDING YOUR RISK FOR DEVELOPING BLOOD CLOTS (VTE) IN CANCER

Faculty of Health, Medicine and Life Sciences

Assessing the uptake of national initiatives

Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.

Deep vein thrombosis outpatient pathway and ultrasound sensitivity

Director Department of Pediatric Hematology & Oncology Delhi, INDIA.

Concurrent chemotherapy and hyperthermia in patients with recurrent cervical cancer after chemoradiation: outcome and survival S.T. Heijkoop1,2; H.C. van.

Prognosis of younger patients in non-small cell lung cancer

UNDERSTANDING YOUR RISK FOR DEVELOPING BLOOD CLOTS (VTE) IN CANCER

Relationship between the site of esophageal carcinoma and survival of patients with locally advanced disease Authors: Andrea Masarykova, Ingrid Zavacka,

OPTIMIZING TREATMENT FOR ADVANCED OVARIAN CANCER:

Marcelo Calil Instituto Brasileiro de Controle do Câncer

930P - A retrospective single institution study evaluating clinical outcome and prognostic markers for endometrial and ovarian carcinosarcomas (CS) U.Asghar1,

Prevalence of Venous Thromboembolism in Cancer Patients in the Emergency Department and associated Healthcare Resource Utilization and Expenditure.

Table 1 Baseline patient characteristics

The heart and science of medicine.

Annie Young PhD Professor of Nursing, University of Warwick, UK

Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer:

Department of Surgery, Taipei Veterans General Hospital Huang Kuo-Hung

Daniel C. Thomas, MD, MPH, Brian N. Arnold, MD, Jessica R

The Burden of Hospital-Associated Venous Thromboembolism

Improved survival outcomes after resection of ductal adenocarcinoma in the body and tail of the pancreas: A single center 10 years’ experience Seong.

Symptomatic venous thromboembolism after femoral vein harvest

Deep venous thrombosis after repair of nonruptured abdominal aneurysm

A Systematic Review of Pulmonary Embolism in Patients With Lung Cancer

Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism–related genes Ruben Pio, PharmD, PhD, Jackeline.

Background: Gene Expression

NOAC Studies in VTE AF Studies Superior Outcomes.

Published online September 20, 2017 by JAMA Surgery

References: Oncological Surgyery: 1. ASCO: Lyman GH, Bohlke K, Khorana AA, et al. Venous Thromboembolism Prophylaxis and Treatment.

Role for XRT in treatment of early stage Follicular lymphoma?

Identifying Low-Risk Patients with Pulmonary Embolism Suitable For Outpatient Treatment A VERITY Registry Pilot Study N Scriven, T Farren, S Bacon, T.

Lung Cancer (C33-C34): 2011 Proportion of Cases Diagnosed at Each Stage, Adults (Aged 15-99), England and Wales Stage Adults Stage I 14.5% Stage II 7.3%

Tom Bird Clinical Oncologist Bristol Haematology & Oncology Centre

Kantarjian HM et al. Blood 2008;112:Abstract 635.

Surgical resection of metachronous liver metastases

Cumulative prevalence of venous thromboembolic events in ITP patients who underwent splenectomy compared with those who did not. Cumulative prevalence.

Deep venous thrombosis after repair of nonruptured abdominal aneurysm

Presentation transcript:

Thromboembolism in Patients with Advanced Ovarian Cancer on Neo-adjuvant Chemotherapy Waleed Alselwi1, Thomas Coventary2, Faisal Azam1 1. King Fahad specialist Hospital –Dammam, KSA. 2. North Wales Cancer centre, Betsi Cadwaladr University Hospital, UK Background Patients (pts) with advanced ovarian cancer (OC) on neo-adjuvant chemotherapy (NACT) are at high risk of developing venous thromboembolism (VTE). Current guidelines do not recommend thromboprophylaxis for ambulatory cancer pt on outpatient treatment. The aim of this study is to evaluate the prevalence of VTE and its impact on survival. Methods We performed a retrospective analysis using case notes of pts with advanced OC treated with NACT at our cancer centre between Apr2010 and May2014. Results A total of 58 pts were treated with NACT. VTE were identified in 17 (29%) pts comprising 6 pulmonary emboli and 11 deep vein thrombosis. Among the 17 pts who developed VTE 4(6.8%) pts had it during NACT, 5(8.6%) were diagnosed before starting NACT and 8 (13%) had it after the surgery. All pts had stage IIIC or IV OC at diagnosis. Median time of VTE from cancer diagnosis was 4 months. As per VTE risk scoring 3(5%) pts were high risk and 14(22%) were intermediate risk. 3 out of 4 patients who developed VTE during NACT were high risk(Table 1) . Median overall survival of patients with VTE was 29 months as compared to 18 months in pts without VTE. None of the pt died of VTE. Table1: Predictive model for chemotherapy-associated VTE in ambulatory cancer patients-Risk score Cancer-related Risk Factors Site of cancer and tumour histotype Number Very high risk (stomach adenocarcinoma, pancreas adenocarcinoma) 2 High risk (lung, lymphoma, gynaecological, bladder, testicular) 1 Conclusion VTE affected 7% pts with advanced OC on NACT. No impact on survival was noted with VTE implying that it is not a poor prognostic factor for this group of pts. Identification of high risk pts before starting NACT will help in pt selection for thromboprophylaxis. Haematological risk factors Number Prechemotherapy platelet count ‡350 000/ll 1 Haemoglobin <10 g/dl or use of ESA growth factors Prechemotherapy leukocyte count >11 000/ll Patient-related Risk Factor Patient-related risk factor Number Body mass index ‡35 kg/m2 1 *Low-risk category (score = 0) *Intermediate-risk category (score = 1–2) *High-risk category (score ≥3)